echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Lancet respirat med: Efficacy analysis of pembrolizumab in the treatment of late-period skin tumors

    Lancet respirat med: Efficacy analysis of pembrolizumab in the treatment of late-period skin tumors

    • Last Update: 2021-04-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Treatment options for malignant pleural mesothelioma (MPM) are limited.


    Treatment options for malignant pleural mesothelioma (MPM) are limited.


    The Phase 2 KEYNOTE-158 study is an ongoing open-label, multi-cohort, single-arm Phase 2 trial that recruits 18-year-olds who are intolerant to standard treatment or who have progressed after treatment, and have EOCG performance status 0-1 Points, MPM patients with tumor samples that can be assessed for biomarkers.


    Objective response rate

    Objective response rate

    From February 9, 2016 to August 16, 2016, a total of 118 patients were enrolled in the MPM cohort and received at least one dose of pembrolizumab.


    Ten patients (8%) achieved objective remission.


    Objective duration of relief

    Objective duration of relief

    6 of 77 MPM patients with PD-L1 positive (8%) achieved an objective response (median response lasted 17.


    6 of 77 MPM patients with PD-L1 positive (8%) achieved an objective response (median response lasted 17.


    OS and PFS

    OS and PFS

    The median overall survival time was 10.


    The median overall survival is 10.


    Adverse events

    Adverse events

    82 (69%) patients had treatment-related adverse events, and 14 (12%) patients had serious adverse events that were considered treatment-related.


    In summary, pembrolizumab exhibits sustained anti-tumor activity and controllable toxicity in patients with advanced MPM, regardless of whether PD-L1 is positive or negative .


    Pembrolizumab exhibits sustained anti-tumor activity and controllable toxicity in patients with advanced MPM, regardless of whether PD-L1 is positive or negative

    Original source:

    Original source:

    Timothy A Yap, et al.


    org/10.
    1016/S2213-2600(20)30515-4" target="_blank" rel="noopener">Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.